Endo Sees Regulatory Setting For Opana ER As "A Moving Target"
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO says company in discussions about "complete response" letter with FDA and will "work through" FDA's safety-first focus.
You may also be interested in...
Opioid Sponsors To Get Help Developing Abuse-Resistant Products From FDA, NIH
Additional research into abuse-deterrent and non-addictive drug formulations is expected as part of the Obama Administration’s prescription drug abuse plan, some of which already is under way.
Remoxy's Abuse Liability Study May Offer Clues On FDA's Upcoming Opioid Guidance
FDA’s response to new data on Remoxy could serve as a model for how the agency expects to deal with the abuse-deterrent formulations it is encouraging for oxycodone and other opioids.
Opioid Sponsors To Get Help Developing Abuse-Resistant Products From FDA, NIH
Additional research into abuse-deterrent and non-addictive drug formulations is expected as part of the Obama Administration’s prescription drug abuse plan, some of which already is under way.